New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 19, 2014
08:48 EDTISISIsis CEO says APOC3 data 'really exciting,' NY Times reports
Following the publication of new studies that independently identified mutations in the APOC3 gene that protect against heart attacks, the CEO of Isis Pharmaceuticals, Stanley Crooke, whose company is developing a drug that counteracts the gene, said, "Trust me, these data are really exciting" and called the product "the most important drug" in the company's pipeline, according to The New York Times. Experts see the findings leading to a push to develop drugs that mimic the effect of the mutations, but caution that drug development takes years and that there are no guarantees that new treatments will succeed, the report noted. Shares of Isis are up 4% in pre-market trading following the study publications. Reference Link
News For ISIS From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
There are no results for ISIS

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use